Compare Eni SpA (E) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Zimmer Biomet Holdings Inc — how do they compare? Eni SpA trades at $55.94 (market cap $79.81B), while Zimmer Biomet Holdings Inc trades at $89.6 (market cap $16.95B). The key difference: Eni SpA is far larger — about 4.7× Zimmer Biomet Holdings Inc's market cap, and Eni SpA pays the higher dividend (4.39%). Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| E | ZBH | |
|---|---|---|
Market Cap | $79.81B | $16.95B |
Volume | 365,912 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $57.61 | $103.98 |
52-Week Low | $34.03 | $79.58 |
Typical Hold Time | 53 Days | 89 Days |
Enterprise Value | $104.34B | $24.02B |
Dividend Yield | 4.39% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $56.02, up 3.82% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85. Recent earnings have been mixed, with Q4 2025 beating estimates but Q1 and Q2 2026 missing. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, though net income margin improved to 5.97% in 2026. Positive news includes expansion in Venezuela, Indonesia, and humanoid robotics partnerships.
Outlook is cautiously optimistic given low valuations and strategic initiatives, but risks include volatile energy prices and execution challenges. Analyst consensus is mixed with 34.6% buy ratings. Earnings growth and operational efficiency are key catalysts for upside, while geopolitical and macroeconomic factors pose headwinds.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
